Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis

Trial Profile

Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Ocrelizumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 27 May 2017 This trial has been completed in Slovakia.
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results reporting updated safety data from the controlled and open-label extension periods of phase II and III clinical trials (ORATORIO, OPERA I, OPERA and WA21493; n=2279) presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top